Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Articles online first > Minerva Gastroenterologica e Dietologica 2018 Jan 10



Publication history
Cite this article as


A Journal on Gastroenterology, Nutrition and Dietetics

Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index



Minerva Gastroenterologica e Dietologica 2018 Jan 10

DOI: 10.23736/S1121-421X.18.02465-0


language: English

Gastroenterology today: between certainties and news: a meeting held in Turin on May 27, 2017

Rinaldo PELLICANO 1 , Davide G. RIBALDONE 1, 2, Marco ASTEGIANO 1, Luca DUGHERA 3, Edda BATTAGLIA 4, Anna MORGANDO 1, Arrigo ARRIGONI 1, Mauro SPANDRE 5, Mario GRASSINI 4, Giorgio M. SARACCO 1, 2, Francis MÉGRAUD 6

1 Unit of Gastroenterology, Molinette Hospital, Turin, Italy; 2 Department of Medical Sciences, University of Turin, Turin, Italy; 3 Digestive Motility and Endoscopy Unit, Department of Medicine, Città della Salute e della Scienza, Turin, Italy; 4 Gastroenterology and Endoscopy Unit, Cardinal Massaia Hospital, Asti, Italy; 5 Unit of Gastroenterology, San Giovanni Bosco, Martini and Maria Vittoria Hospitals, Turin, Italy; 6 Department of Bacteriology, INSERM U1053, Université de Bordeaux, Bordeaux, France


This special article reports on two crucial issues discussed during a meeting. The first was the updated management of Helicobacter pylori infection. This was approached taking into account the recent European Guidelines, with a focus on novelties in treatment. In particular, considering the increasing H. pylori antibiotic resistance to clarithromycin, in countries with a high clarithromycin resistance rate the bismuth-containing quadruple therapies should be preferred. The new formulation, with bismuth, metronidazole, and tetracycline contained in a single capsule (three-in-one), has shown exciting results both in naive and in non-responder patients. Levofloxacin- and rifabutin-containing triple therapies should be proposed to patients who experienced H. pylori treatment failures. Another key message on H. pylori management was that, after one or more failures, standard antimicrobial susceptibility testing should be considered before prescribing a further treatment. The second issue concerned the novelties on dysbiosis of intestinal microbiota and its clinical consequences. Among the latter, the focus was on both constipation-predominant irritable bowel syndrome (IBS-C) and microscopic colitis. Since the number of microorganisms inhabiting the gastrointestinal (GI) tract is estimated to be about 10 times higher than that of human cells, it is not surprising to foresee the clinical consequences of dysbiosis. However, to date the role of dysbiosis in IBS-C and in microscopic colitis is poorly known and major efforts are needed to understand if manipulating microbiota could improve the treatment of these and other diseases both within and outside the GI tract.

KEY WORDS: Colitis - Helicobacter pylori - Irritable bowel syndrome - Maastricht V - Microbiome

top of page

Publication History

Article first published online: January 10, 2018
Manuscript accepted: January 4, 2018
Manuscript received: December 10, 2017

Cite this article as

Pellicano R, Ribaldone DG, Astegiano M, Dughera L, Battaglia E, Morgando A, et al. Gastroenterology today: between certainties and news: a meeting held in Turin on May 27, 2017. Minerva Gastroenterol Dietol 2018 Jan 10. DOI: 10.23736/S1121-421X.18.02465-0

Corresponding author e-mail